Senior Management

PACT Pharma

Alex Franzusoff, Ph.D.

Chief Executive Officer

Dr. Franzusoff joined PACT Pharma in January 2017. Previously, he was consulting for several private and public biotech/pharma companies in the I-O space, in addition to his role as founder and CEO of Krypton Immuno-oncology. At Bavarian Nordic, he worked at the forefront of the electrified I-O space as SVP R&D, which resulted in the $1B deal with BMS for Prostvac, its Ph3 cancer immunotherapy product. He had returned to California for that role, from Boston, after serving as Chief Executive Officer and Board Director for AZTherapies, developing Alzheimer’s therapies based on re-purposing previously approved drugs via the 505(b)2 pathway for Phase 3 studies. He previously led the venture-backed Permeon Biologics as President and a member of the board of directors. Dr. Franzusoff’s career in the biotechnology industry was launched with the co-founding of the biotech GlobeImmune, Inc., where he served as Vice President of Research & Development for immunotherapy against cancer & infectious diseases.

Dr. Franzusoff trained as a Postdoctoral Fellow with the Nobel Laureate, Dr. Randy Schekman, at the University of California, Berkeley after earning his Ph.D. in Biochemistry at SUNY at Stony Brook. He was a tenured Associate Professor at the University of Colorado, School of Medicine until 2004.

Jeroen Grasman, M.B.A.

Vice President, Finance and Corporate Treasurer

Jeroen Grasman, M.B.A. joins PACT as Vice President, Finance and Corporate Treasurer is responsible for the Company’s finance, accounting, information technology, facility and procurement functions. Jeroen has more than 20 years of experience in finance and operations, most recently as Vice President, Finance at Intarcia Therapeutics. At Intarcia, he served as finance head for manufacturing and global commercialization of its MediciTM Drug Delivery System. Prior to Intarcia, Mr. Grasman spent 11 years at Genentech-Roche, where he held positions of increasing responsibility in Strategic Planning, Business Development Finance, R&D Finance and finally as global finance head for Biologics Manufacturing at Roche. Mr. Grasman received an MBA at Harvard Business School and an MS in Statistics and Operations Research at the University of Groningen.

Stefanie Mandl, Ph.D.

Vice President, Translational Immunology

Stefanie Mandl, Ph.D. has been appointed to the role of Vice President, Translational Immunology. She is responsible for leading PACT’s personalized neoTCR-T cell engineering, adoptive T cell therapy product characterization and immune monitoring/biomarker development. Dr. Mandl has extensive experience in the development of immunotherapies for the treatment of cancer and infectious disease. Dr. Mandl joined PACT Pharma in April of 2017 as the Senior Director, Tumor Immunology. Prior to PACT, she was the Senior Director, Immunology at Cidara Therapeutics, to direct scientific development of the CloudbreakTM platform for the treatment of infectious disease. Before Cidara, Stefanie worked 9 years at Bavarian Nordic, most recently as the Director, Pre-clinical Oncology Research. Dr. Mandl’s experience in cancer immunotherapy began in Berlin, where she received her MS in Biology from Freie Universität Berlin, then earned her PhD in Immunology at the University of California San Francisco and trained as a postdoctoral fellow at Stanford University.

Atulya Agarwal, J.D., Ph.D.

General Counsel and Corporate Secretary

Atulya Agarwal, J.D., Ph.D., joins PACT as General Counsel and Corporate Secretary, with oversight of all corporate legal functions, including compliance, IP and licensing-related activities. Dr. Agarwal is a seasoned attorney with more than 25 years in the biotech and pharmaceutical industries. Fifteen of those were spent at Genentech, where he held various roles of increasing responsibility, including the Head of IP Licensing and Business Strategy as well as the Head of Patents for Genentech’s Oncology franchise.

Dr. Agarwal also has held the positions of Chief IP officer at Elan Pharmaceuticals and partner at Dickstein Shapiro, where his practice focused on all aspects of IP strategy, including IP diligence, contract drafting and negotiation, IP enforcement, and U.S. and foreign patent prosecution. Dr. Agarwal received a J.D. from Santa Clara University School of Law, a Ph.D. in Biochemistry from Boston University School of Medicine and a B.S. in Biochemistry from the Pennsylvania State University.

Gregg Fine, M.D.

Vice President, Clinical Development

Gregg Fine, M.D., joins PACT as Vice President, Head of Clinical Development and is responsible for the clinical development strategy and medical oversight of the Company’s portfolio. Gregg has more than a decade of experience in drug development and most recently served as the Development Leader for Genentech’s RNA-based personalized neoantigen cancer vaccine program. Previously he served as the Global Development Team Leader at Roche for the genitourinary franchise of TECENTRIQ® and led the program from Phase I through the initial BLA approval for bladder cancer and beyond to expansion in Phase I-III studies in RCC and prostate cancer. Gregg also worked on pivotal programs for GAZYVA® and RITUXAN®.

Dr. Fine obtained his baccalaureate from Colgate University and his medical degree from the University of Vermont College of Medicine. He completed his residency in Internal Medicine at Yale-New Haven Hospital and his fellowship in Hematology/Oncology at the Beth Israel Deaconess Medical Center/Harvard Cancer Center where his area of research interest was in clinical informatics. Dr. Fine is board certified in medical oncology.